Albany Molecular Research (AMRI) Tops Q3 EPS by 1c

Go back to Albany Molecular Research (AMRI) Tops Q3 EPS by 1c

AMRI Announces Third Quarter 2015 Results

November 5, 2015 7:02 AM EST

ALBANY, N.Y., Nov. 5, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September 30 2015.

Highlights:

Third quarter contract revenue of $101.4 million, a 76% increase from 2014 Adjusted contract margins expand to 25% Third quarter adjusted diluted EPS of $0.14, including a $0.04 decrease in EPS from royalties in the current quarter Operating cash flow of $18.5 million Reiterates Full Year 2015 total revenue of $400 to $416 million; adjusted EPS guidance maintained at between... More